Skip to content

Nuvalent, Inc. NUVL Pre-Tax Income

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
$3.17B+13.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.79M-387%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$453.82M-113%
Incyte logo
IncyteINCY
$343.6M+46.7%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$299.2M+372%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s pre-tax income?
Nuvalent, Inc. (NUVL) reported pre-tax income of -$109.11M in Q1 2026.
How has Nuvalent, Inc.'s pre-tax income changed year-over-year?
Nuvalent, Inc.'s pre-tax income decreased by 29.2% year-over-year, from -$84.43M to -$109.11M.
What is the long-term trend for Nuvalent, Inc.'s pre-tax income?
Over 3 years (2022 to 2025), Nuvalent, Inc.'s pre-tax income has grown at a 73.1% compound annual growth rate (CAGR), from -$81.85M to -$424.79M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.